Never say die: survival signaling in large granular lymphocyte leukemia.
Large granular lymphocyte (LGL) leukemia is a rare disorder of mature cytotoxic T or natural killer cells. Large granular lymphocyte leukemia is characterized by the accumulation of cytotoxic cells in blood and infiltration in the bone marrow, liver, and spleen. Herein, we review clinical features of LGL leukemia. We focus our discussion on known survival signals believed to play a role in the pathogenesis of LGL leukemia and their potential therapeutic implications.
Penn State Hershey Cancer Institute, Hershey, PA, USA.
Mithun Vinod
MV
Shah
Ranran
R
Zhang
Thomas P
TP
Loughran
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D016923:Cell Death; D002470:Cell Survival; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D053222:Fas Ligand Protein; D006801:Humans; D016130:Immunophenotyping; D054066:Leukemia, Large Granular Lymphocytic / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy*; D008495:Medical Oncology / Q000379:methods; D051379:Mice; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000166:cytology / Q000473:pathology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D053222:Fas Ligand Protein; D048049:Extracellular Signal-Regulated MAP Kinases